Sample Page
Author:
SAB Biotherapeutics, Inc.
Posted Date:
May 5, 2026
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
SAB Biotherapeutics, Inc.
May 5, 2026
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
SAB Biotherapeutics, Inc.
April 22, 2026
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
SAB Biotherapeutics, Inc.
April 15, 2026
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
SAB Biotherapeutics, Inc.
March 19, 2026
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
SAB Biotherapeutics, Inc.
March 17, 2026
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SAB Biotherapeutics, Inc.
March 17, 2026
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
SAB Biotherapeutics, Inc.
March 10, 2026
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
SAB Biotherapeutics, Inc.
March 9, 2026
SAB BIO to Participate in Upcoming Investor Conferences
SAB Biotherapeutics, Inc.
March 2, 2026
SAB BIO to Participate in Upcoming Investor Conferences
SAB Biotherapeutics, Inc.
February 4, 2026
